The Evaluation of the Efficacy and Safety of Donepezil Hydrochloride in Subjects With Mild Cognitive Impairment (MCI)

• Status: Completed
• Trial end date: 2007-03-01
• Target enrollment: 0
• Participant gender: All

Summary

To investigate the efficacy and safety of donepezil in individuals with mild cognitive impairment on measures of cognition, global function and behavior.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Eisai Inc.
• Collaborator: Pfizer
• Treatments: Donepezil

Criteria

Inclusion Criteria:

• Memory complaint

• Mini Mental Status Exam (MMSE) score 24-28 inclusive

• General cognition and function performance sufficiently preserved such that a diagnosis of Alzheimer's disease (AD) cannot be made

• Generally healthy and ambulatory

• Sufficiently fluent in English

Exclusion Criteria:

• Diagnosis of probable or possible AD

• Neurological disorders

• History of malignant cancers

• Previously have taken donepezil or other acetylcholinesterase (ChE) inhibitors for more than 1 month or in the past 3 months prior to study entry